McAlpine J B, Karwowski J P, Jackson M, Mullally M M, Hochlowski J E, Premachandran U, Burres N S
Pharmaceutical Products Research and Development Abbott Laboratories, Abbott Park, Illinois 60064.
J Antibiot (Tokyo). 1994 Mar;47(3):281-8. doi: 10.7164/antibiotics.47.281.
In the course of screening with the mixed lymphocyte reaction, a new inhibitor of protein kinase C with immunosuppressive activity was isolated from the fermentation broth and mycelia of Streptomyces sp. AB 1869R-359. Although certain similarities exist, this strain is morphologically and physiologically distinct from other reported producers of staurosporine-related compounds. We have found that this strain produces relatively high levels of staurosporine and the new minor compound MLR-52, which possesses the indolo[2,3-a]carbazole chromophore of staurosporine, but differs in the substitution pattern of the sugar moiety. Their structures have been elucidated by mass and NMR spectra. MLR-52 has been shown to inhibit the enzymatic activity of protein kinase C and the murine mixed lymphocyte reaction.
在用混合淋巴细胞反应进行筛选的过程中,从链霉菌属AB 1869R - 359的发酵液和菌丝体中分离出一种具有免疫抑制活性的新型蛋白激酶C抑制剂。尽管存在某些相似之处,但该菌株在形态和生理上与其他已报道的星形孢菌素相关化合物产生菌不同。我们发现该菌株产生相对高水平的星形孢菌素和新的次要化合物MLR - 52,MLR - 52具有星形孢菌素的吲哚并[2,3 - a]咔唑发色团,但在糖部分的取代模式上有所不同。它们的结构已通过质谱和核磁共振光谱得以阐明。MLR - 52已被证明可抑制蛋白激酶C的酶活性和小鼠混合淋巴细胞反应。